NEW YORK, Nov. 14, 2014 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Aeterna Zentaris,
Inc. ("Aeterna" or the "Company") (NASDAQ: AEZS). Such
investors are advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
237.
The investigation concerns whether Aeterna and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On November 6, 2014, the Company
announced that it had received a Complete Response Letter ("CRL")
from the FDA, advising that it would not approve the Company's
MACRILEN NDA. The Company stated that the FDA's letter
advised the Company that: "the planned analysis of the Company's
pivotal trial did not meet its stated primary efficacy objective as
agreed to in the Special Protocol Assessment agreement letter
between the Company and the FDA." The CRL further raised
issues related to the lack of complete and verifiable source data
for determining whether patients were accurately diagnosed with
AGHD. The FDA concluded that, "in light of the failed primary
analysis and data deficiencies noted, the clinical trial does not
by itself support the indication."
On this news, shares of Aeterna fell $0.64 per share, or more than 49.60%, to close at
$0.65 per share on November 6, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San
Diego and Florida, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the
dean of the class action bar, the Pomerantz Firm pioneered the
field of securities class actions. Today, more than 70 years later,
the Pomerantz Firm continues in the tradition he established,
fighting for the rights of the victims of securities fraud,
breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of
class members. See www.pomerantzlaw.com.
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
SOURCE Pomerantz LLP